Wael M. ElShamy, Ph.D.

Associate Professor
Metastatic Cancer

Research Focus

Dr. ElShamy obtained his B.Sc. in Chemistry in 1986 from the Ayn-Shams University in Egypt, and his Ph.D. in Medical Biochemistry and Biophysics from the Royal Karolinska Institute in Sweden, in 1998. After completing a post-doctoral fellowship in Dana-Farber Cancer Institute and Harvard Medical School he became an instructor at Harvard Medical School. He was the Dr. Lawrence and Mrs. Bo Hing chan Tseu American Cancer Society Research Scholar from 2009 to 2013. Most recently, he was Director of the Molecular Cancer Therapeutic Program at the University of Mississippi Medical Center’s Cancer Institute. He joined SDBRI in 2017.


Ph.D. in Medical Biochemistry & Biophysics, Stockholm Karolinska University, 1998
MS in Molecular Neurobiology, Stockholm University, 1995
MS in Biochemistry, Stockholm University 1993
BS in Chemistry, Ayn-Shams University, 1986

Professional Experience

2017 – Present, Current Associate Professor, San Diego BioMed
2011 – 2017 Associate Professor, Radiation Oncology, University of Mississippi
2008 – 2010 Assistant Professor, Pathology, University of Hawai’i
2006 – 2007 Assistant Professor, Pharmacology, Loyola University
2002 – 2006 Instructor, Medicine, Harvard Medical School
1998 – 2002 Post-doctoral Fellow, Cancer Biology, Dana-Farber Cancer Institute

Honors and Awards

Dr. Lawrence and Mrs. Bo Hing chan Tseu American Cancer Society Research Scholar, 2009 – 2013
Royal Karolinska Foundation Travel Fellowship, 1998

Professional Activities

Chair, San Diego BioMed, IBC Committee, 2018 – Present
Peer Review, US Army Reserve Medical Corps Breast Cancer Program, 2017 – Present
Peer Review, NIH 2017 – Present
U.S. Patent No. 9,075,071: “Methods for Diagnosis and Treatment of Cancer”, 2015
U.S. Patent No. 9,303,069: “Peptides for Treating Cancer”, 2015
Director, Molecular Cancer Therapeutics, Cancer Institute, University of Mississippi Medical Center, 2011 – 2017
Member, American Society of Pathology, 2008 – Present
Member, American Society of Pharmacology and Experimental Therapeutics, 2006 – Present
Member, American Society for Microbiology, 2005 – Present
Member, American Association for Cancer Research, 2005 – Present
Mass. Dept. of Public Health Post-Doctoral Fellowship, 2001 – 2003
Human Frontiers Post-Doctoral Fellowship, 1999 – 2001
EMBO Post-Doctoral Fellowship, 1999 – 2001
Member, Neuroscience Society, 1996 – Present

Select Publications

Sami E, Paul BT, Koziol JA, ElShamy WM. The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages. Cancer Res. 2020 Mar 1;80(5):1102-1117.


Sami E, Bogan D, Molinolo A, Koziol J, ElShamy WM. The molecular underpinning of geminin-overexpressing triple-negative breast cancer cells homing specifically to lungs. Cancer Gene Ther. 2022 Mar;29(3-4):304-325. doi: 10.1038/s41417-021-00311-x. Epub 2021 Mar 15. PMID: 33723406

Castillo P, Aisagbonhi O, Saenz CC, ElShamy WM. Novel insights linking BRCA1-IRIS role in mammary gland development to formation of aggressive PABCs: The case for longer breastfeeding. Am J Cancer Res. 2022 Jan 15;12(1):396-426. eCollection 2022. PMID: 35141026

Ryan D, Sinha A, Bogan D, Davies J, Koziol J, ElShamy W. A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment. Oncotarget. 2017 8:103182-103206.


Sinha A, Paul BT, Sullivan LM, Sims H, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Oncotarget. 2017 Feb 7;8(6):10114-10135.


Blanchard Z, Paul BT, Craft B, ElShamy WM. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Breast Cancer Res. 2015 Jan 13;17:5.


Blanchard Z, Mullins N, Ellipeddi P, Lage JM, McKinney S, El-Etriby R, Zhang X, Isokpehi R, Hernandez B, Elshamy WM. Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative. PLoS One. 2014 Apr 30;9(4):e95663.


Gardner L, Malik R, Shimizu Y, Mullins N, ElShamy WM. Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells. Breast Cancer Res. 2011 May 19;13(3):R53.


All of Dr. Wael ElShamy’s Publications

We need your help

Our research programs are funded primarily by grants from the National Institutes of Health (NIH). Private donations help to accelerate the progress of research through the purchase of laboratory supplies and equipment or the recruitment of additional laboratory personnel. Thank you!

Donate Now